Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR
CNBC's “Halftime Report” team discuss their top stocks and final trades.
Fiscal Year: January - December
Vertex Pharmaceuticals Incorporated (VRTX), listed on the NASDAQ, has a market capitalization of $. As of Oct 04, 2025, the stock is trading at $403.30 per share, offering investors a clear view of its current market value. Vertex Pharmaceuticals Incorporated is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 28.66, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Vertex Pharmaceuticals Incorporated also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Vertex Pharmaceuticals Incorporated (VRTX) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Vertex Pharmaceuticals Incorporated is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Vertex Pharmaceuticals Incorporated, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Vertex Pharmaceuticals Incorporated is 29.55, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Vertex Pharmaceuticals Incorporated (VRTX) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Vertex Pharmaceuticals Incorporated (VRTX) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Vertex Pharmaceuticals Incorporated (VRTX) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Vertex Pharmaceuticals Incorporated. To access the full SS Score, consider upgrading your subscription.
Vertex Pharmaceuticals Incorporated is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 28.66. Investors should compare these metrics with industry peers to gauge whether Vertex Pharmaceuticals Incorporated is outperforming or underperforming within its sector.
Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important advancements across its programs in immunoglobulin A Nephropathy (IgAN), APOL1-mediated ki...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball world champion Jayson Tatum to raise awareness of JOURNAVX® (...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bank of America Global Healthcare Conference 2025 September 23, 2025 3:10 AM EDT Company Participants Susie Lisa - Senior Vice President of Investor ...
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (T...
Vertex Pharmaceuticals remains a buy, anchored by its dominant cystic fibrosis (CF) franchise and optionality in JOURNAVX. VRTX's near-term growth hinges on JOURNAVX's commercial ramp and pivotal diab...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year's Lasker~DeBakey...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 11:30 AM EDT Company Participants Reshma Kewalramani - CEO, President & Dir...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 11:00 AM EDT Company Participants Susie Lisa - Senior Vice President of Investor...
LA JOLLA, Calif.--(BUSINESS WIRE)-- #ADC--Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor...
This week's Undercovered Dozen spotlights 12 lesser-known stocks and ETFs, offering unique investment opportunities across gold, biotech, income, and tech sectors. B2Gold and Vertex Pharmaceuticals st...
A 20% drop in Vertex Pharmaceuticals' stock price since I wrote last month was the impetus to make a re-assessment. But the rating has remained unchanged at Hold. This is despite significantly improve...
The recent Vertex Pharmaceuticals Incorporated stock drop after VX-993 trial results is overblown; the pain franchise remains robust with multiple promising avenues and ongoing trials. Vertex's CF fra...
Vertex Pharmaceuticals Inc. VRTX stock is falling on Tuesday after the company's pain data overshadowed strong second-quarter earnings.
Vertex Pharmaceuticals Inc VRTX reported better-than-expected earnings for the second quarter after the market close on Monday.
Shares of Vertex Pharmaceuticals (VRTX) sank 15% Tuesday, a day after the drugmaker announced a study showed its experimental pain medicine was not successful, and it would no longer move forward with...
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Charles F. Wagner - Executive VP, COO & CFO Duncan McKechnie - Corpor...
Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic fibrosis drug and product launches.
The biotechnology company's stock fell in post-market trading, after saying it would not progress a next-generation pain treatment into advanced testing.
CNBC's Angelica Peebles reports on Vertex Pharmaceuticals latest earnings report, including announcements that its CSO plans to retire August 2026.
Vertex Pharmaceuticals said on Monday it will not continue development of its experimental non-opioid painkiller as a solo treatment after it failed to meet the main goal of a mid-stage trial.
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
Year | FCF Estimate | % | # Analysts |
---|---|---|---|
2025 | 2.02B | -355.04% | Est @-355.0% |
2026 | 4.82B | 139.21% | Analyst x4 |
2027 | 5.31B | 10.10% | Analyst x3 |
2028 | 5.91B | 11.25% | Analyst x3 |
2029 | 6.64B | 12.42% | Analyst x3 |
2030 | 7.06B | 6.29% | Est @6.3% |
2031 | 7.42B | 5.10% | Est @5.1% |
2032 | 7.73B | 4.26% | Est @4.3% |
2033 | 8.02B | 3.68% | Est @3.7% |
2034 | 8.26B | 3.05% | Est @3.0% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
Year | FCF | Discount Factor | PV of Future FCF |
---|---|---|---|
2023A | 3.34B | 1.00 | 3.34B |
2024A | -790.30M | 1.00 | -790.30M |
2025E | 2.02B | 1.08 | 1.87B |
2026E | 4.82B | 1.17 | 4.14B |
2027E | 5.31B | 1.26 | 4.22B |
2028E | 5.91B | 1.36 | 4.34B |
2029E | 6.64B | 1.47 | 4.52B |
2030E | 7.06B | 1.58 | 4.45B |
2031E | 7.42B | 1.71 | 4.33B |
2032E | 7.73B | 1.85 | 4.19B |
2033E | 8.02B | 1.99 | 4.02B |
2034E | 8.26B | 2.15 | 3.83B |
Terminal | 154.64B | 2.15 | 71.79B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.